China Contract Research Organization (CRO) Industry Report, 2019-2025
  • Mar.2019
  • Hard Copy
  • USD $3,100
  • Pages:150
  • Single User License
    (PDF Unprintable)       
  • USD $2,900
  • Code: ZLC074
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,300
  • Hard Copy + Single User License
  • USD $3,300

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global contract research organization (CRO) market. Global CRO industry size sustained growth of around 8% over the years, reaching roughly $37.1 billion in 2018. 

There are more than 1,100 CRO companies around the globe, led by IQVIA, Covance, LabCorp, Syneos, Charles River, Parexel, ICON, PRA, PPD and Wuxi AppTec. The world’s top ten CRO players hold a combined over 50% market share for now.

CRO 1_副本.png

China’s great competitive edge over the developed countries in pharmaceutical R&D cost has allured several large international pharmaceutical companies to build dozens of R&D centers here, boosting the country’s CRO industry which was worth RMB68.7 billion in 2018. The world-renowned players will continue R&D budget tilt toward CRO services and Chinese firms with more expenses on research and development will still be beneficiaries as more new drugs are approved and favorable policies are implemented. It is expected that Chinese CRO industry scale will reach a staggering RMB242.5 billion in 2025.

Large multinational and local companies play the key role in the Chinese CRO market. Thereof, global big-names or their branches in China, for instance, IQVIA, LabCorp and Parexel remain strong in research and development and capital, offering preclinical and clinical trial services.

Chinese CRO leaders include Wuxi AppTec, Pharmaron, Meidicilon, Shanghai ChemPartner, Tigermed and Joinn Laboratories. As one of the most comprehensive service platforms integrating discovery, research and development of small-molecule chemical drugs, WuXi AppTec with the strongest R&D strength not only runs the China’s largest small-molecule pharmaceutical R&D service business but leads the way in global market. It seized about 10.1% of the world’s CRO market in 2018.

CRO 2_副本.png

The CRO industry in China will show three trends below:

1. CRO firms are likely to expand by way of mergers and acquisitions.
Seen from the development course of multinational CRO companies, giants expanded their business through mergers and acquisitions for better performance and greater profitability. Among them, IQVIA, Charles River, Parexel, ICON and PPD each made over 20 acquisitions over the past two decades. Also, Chinese CRO competitors follow suit to sharpen their competitiveness in recent year.

CRO 3_副本.png

2. Favorable policies and capital promote the development of local Chinese companies.
Propelled by favorable policies and capital, Chinese CRO companies have landed in the capital market and raised funds to enhance their competitive strength.

CRO 4_副本.png

3. The industry heads toward vertical integration
Given the importance of data cohesion between new drug R&D phases and the trustworthiness of experimental results, companies that only provide single-stage pharmaceutical R&D services cannot meet the R&D requirements of large pharmaceutical companies on the entire industry chain. Therefore, future entrants need to not only provide quality R&D and production services in their advantageous fields, but also offer comprehensive and integrated new drug research, development and production services through establishment, cooperation or M&A in the upstream and downstream of the industry chain upon customers’ demand.

At present, Wuxi AppTec, taking up nearly 10% share of Chinese CRO market, is able to provide customers with integrated new drug R&D and production services as the industry’s absolute leader. In the future, CRO companies will try to expand their service scope, like extending to CMO/CDMO services, and they will establish a comprehensive service platform covering the entire drug development value chain by enriching their product portfolio constantly through investment in new technologies and new facilities.

1. Overview of Pharmaceutical Outsourcing
1.1 Definition
1.2 Classification
1.3 CRO

2. Evolution of Global CRO Industry
2.1 Development History
2.2 Development Background
2.2.1 Pharmaceutical Industry Size
2.2.2 Pharmaceutical Companies Development
2.2.3 Pharmaceutical R&D
2.3 Market Size
2.4 Competitive Landscape

3. CRO Industry in China
3.1 Development Environment
3.1.1 Regulation
3.1.2 Policy Environment
3.1.3 Industry Environment
3.2 Status Quo
3.3 Market Size
3.4 Competitive Landscape
3.5 Development Trend
3.5.1 Transnational Pharmaceutical Companies Shut Down and Have a Clearance Sale of Their Research Centers in China, which Favors Local Chinese Companies
3.5.2 New Drug Approvals Increase and R&D Expenses Grow, Setting the Stage for CRO Industry
3.5.3 The Amounting Pressure from R&D Costs Make Pharmaceutical Enterprises Rely More on CRO Companies for the Research and Development of New Drugs
3.5.4 Favorable Policies and Capital Promote the Development of Local Chinese Companies
3.5.5 Good Prospects Attract the Enterprises’ Access into CRO Industry
3.5.6 The Industry Heads toward Vertical Integration
3.5.7 M&A May Become the Main Way for CRO Companies to Expand
3.5.8 The Comprehensive Implementation of Consistency Assessment Brings Development Opportunities to the CRO Industry

4. Major Chinese Companies
4.1 Wuxi AppTec
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 Major Clients
4.1.6 R&D Investment
4.1.7 CRO Business
4.1.8 Development Strategy
4.2 Hangzhou Tigermed
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D Investment
4.2.6 Development Strategy
4.3 Guangzhou Boji Pharmaceutical
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D Investment
4.3.6 Development Strategy
4.4 Shanghai Meidicilon Inc.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D Investment
4.4.6 Major Clients
4.4.7 Development Strategy
4.5 Porton Fine Chemicals
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 R&D Investment
4.5.6 Major Clients
4.5.7 Development Strategy
4.6 Joinn Laboratories
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R&D Investment
4.6.6 Major Clients
4.6.7 Development Strategy
4.7 Pharmaron
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D Investment
4.7.6 Major Clients
4.7.7 Development Strategy
4.8 Obio Technology (Shanghai)
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 R&D Investment
4.8.6 Major Clients
4.8.7 Development Strategy
4.9 Nanjing Huawe Medicine Technology Group Co., Ltd.
4.9.1 Profile
4.9.2 Major Clients
4.9.3 Main Business
4.10 Shanghai ChemPartner
4.10.1 Profile
4.10.2 Main Business
4.10.3 Revenue Structure
4.10.4 Major Clients

5 Major Foreign Companies
5.1 LabCorp
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 CRO Business
5.1.5 Development in China
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Development Strategy
5.2.5 Development in China
5.3 Parexel
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Development in China
5.4 Charles River
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Development in China
5.5 PPD
5.5.1 Profile
5.5.2 Development in China
5.5.3 BioDuro
5.5.4 Excel PharmaStudies
5.6 Syneos Health
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 CRO Business
5.6.5 Development in China
5.7 PRA
5.7.1 Profile
5.7.2 Operation
5.7.3 Development in China
5.8 ICON
5.8.1 Profile
5.8.2 Operation
5.8.3 Revenue Structure
5.8.4 Development in China
Classification of Pharmaceutical Outsourcing
R&D Process of New Drugs
Corresponding Relationship between New Drug R & D Process, New Drug R & D Discipline and CRO Services
New Drug R&D Cost Structure
Global Pharmaceutical Market Size, 2012-2018
Global Pharmaceutical Market Size, 2018-2025E
Global Pharmaceutical Market Size (by Type), 2012-2018
Global Pharmaceutical Market Size (by Type), 2012-2025E
Global Pharmaceutical Market Size (by Region), 2012-2018E
Global Pharmaceutical Market Size (by Region), 2018-2025E
TOP20 Pharmaceutical Companies by Revenue, 2017
New Drug Approvals of Global Pharmaceutical Companies (by Company Size), 2013-2022E
Global Pharmaceutical R & D Investment (by Company Size), 2013-2018
Global Pharmaceutical R & D Investment (by Company Size), 2018-2025E
Global Pharmaceutical R & D Investment (by Medicine Type), 2013-2018
Global Pharmaceutical R & D Investment (by Medicine Type), 2018-2025E
Average Costs of New Drugs from R&D to Approved Launch
Cumulative Success Rate of New Drug R&D from Phase I to III 
Number of Drugs in R&D (by Phase), 2017 VS 2016
Scale and YoY Growth of Global CRO Industry, 2011-2018
Scale and YoY Growth of Global CRO Industry, 2018-2025E
Comparison between Global Major CRO Companies
Market Share of Major Global CRO Companies, 2018
M&A Cases of Global Major CRO Companies
Comparison of Major Global CRO Companies by Revenue, 2014-2018
Policies on China’s CRO Industry, 2010-2018 
China Pharmaceutical Market Size and % in Global Total, 2012-2018
China Pharmaceutical Market Size and % in Global Total, 2018-2025E
China Pharmaceutical Market Size (by Type), 2012-2018
China Pharmaceutical Market Size (by Type), 2018-2025E
China Pharmaceutical R & D Investment and % in Global Total, 2013-2018
China Pharmaceutical R & D Investment and % in Global Total, 2018-2025E
Development Course of CRO Industry in China
Comparison of Pharmaceutical R&D Costs in China and Developed Countries
Cases of Multinational Pharmaceutical Enterprises’ R&D Centers in China, 2001-2018
Scale and YoY Growth of China’s CRO Industry, 2011-2018
Scale and YoY Growth of China’s CRO Industry, 2018-2025E
Layout of Major Global CRO Companies in Asia
Comparison of Major Chinese CRO Companies
Market Share of Major Chinese CRO Companies, 2017
Market Share of Major Chinese CRO Companies, 2018
Comparison of Major Chinese CRO Companies by Revenue, 2014-2018
Comparison of Major Chinese CRO Companies by Net Income, 2014-2018
Listing of Local Chinese CRO Companies
Layout of Chinese Companies in CRO, 2015-2017
M & A Cases of Chinese CRO Companies, 2016-2018
China's Policies on Consistency Assessment, 2012-2018
Major Business of Wuxi AppTec
Serivce Provided by Wuxi AppTec to Pharmaceutical Companies in New Medicine R&D Stage
Revenue and Net Income of Wuxi AppTec, 2014-2018
Revenue of Wuxi AppTec by Product, 2015-2018
Revenue of Wuxi AppTec by Region, 2014-2017
Revenue Structure of Wuxi AppTec by Region, 2014-2017
Gross Margin of Wuxi AppTec, 2015-2018
Gross Margin of Wuxi AppTec by Product, 2015-2018
Revenue from Top Ten Clients of Wuxi AppTec, 2015-2017
R&D Investment and % of Total Revenue of Wuxi AppTec, 2014-2018
IPO Raised Investment Projects of Wuxi AppTec
Revenue from CRO Business (by Sector) of Wuxi AppTec, 2014-2018
Gross Margin of CRO Business (by Sector) of Wuxi AppTec, 2014-2018
Revenue and Net Income of Tigermed, 2013-2018
Revenue of Tigermed by Business, 2014-2018
Revenue Structure of Tigermed by Business, 2014-2018
Revenue of Tigermed by Region, 2014-2018
Revenue Structure of Tigermed by Region, 2014-2018
Gross Margin of Tigermed by Business, 2014-2018
R&D Investment of Tigermed and % of Total Revenue, 2013-2018
Expansion Course of Tigermed, 2004-2017
Main Business of Boji Medical Biotechnological
Revenue and Net Income of Boji Medical Biotechnological, 2014-2018
Revenue of Boji Medical Biotechnological by Business, 2014-2018
Revenue Structure of Boji Medical Biotechnological, 2014-2018
Gross Margin of Boji Medical Biotechnological by Product, 2014-2018
R&D Investment of Boji Medical Biotechnological and % of Total Revenue, 2014-2018
IPO Project Progress of Boji Medical Biotechnological, as of H1 2018
Development Course of Meidicilon
Revenue and Net Income of of Meidicilon, 2014-2016
Revenue of Meidicilon by Business, 2014-2016
Revenue Structure of Meidicilon by Business, 2014-2016
Revenue of Meidicilon by Region, 2014-2016
Gross Margin of Meidicilon by Business, 2014-2016
R&D Investment of Meidicilon and % of Total Revenue, 2014-2016
IPO Fund-raised Projects of Meidicilon, 2017
Top Five Clients of Meidicilon and % in Total Revenue, 2014-2016
Revenue and Net Income of Porton, 2014-2018
Revenue of Porton by Business, 2014-2017
Revenue Structure of Porton by Business, 2014-2017
Revenue of Porton by Region, 2014-2018
Revenue Structure of Porton by Region, 2014-2018
Gross Margin of Porton by Business, 2014-2017
R&D Investment of Porton and % of Total Revenue, 2014-2017
Subscription of Porton in Establishment of the Industrial Fund, 2019
Revenue from Top 5 Clients of Porton and % in Total Revenue, 2015-2017
Revenue and Net Income of JOINN Laboratories, 2014-2018
Revenue of JOINN Laboratories (by Business), 2014-2018
Revenue Structure of JOINN Laboratories (by Business), 2014-2018
Gross Margin of JOINN Laboratories, 2014-2018
Business Advantages of JOINN Laboratories
R & D Expenditure of JOINN Laboratories and % of Total Revenue, 2014-2018
Investment Projects of JOINN Laboratories by Raising Funds via IPO, 2017
JOINN Laboratories’ Revenue from Top 5 Clients and % of Total Revenue, 2014-2017
Pharmaron’s Revenue and Net Income, 2014-2018
Pharmaron’s Revenue (by Business), 2014-2018
Pharmaron’s Revenue (by Region), 2015-2018
Pharmaron’s Gross Margin, 2015-2018
Pharmaron’s Gross Margin (by Business), 2015-2018
Composition of Pharmaron’s R & D Division
Pharmaron’s Staff Structure by Division, as of June 30, 2018
Pharmaron’s M&A Cases, 2016-2017
Pharmaron’s Revenue from Top 5 Clients and % of Total Revenue, 2014-2018
Revenue and Net Income of Obio Technology (Shanghai), 2014-2018
Revenue of Obio Technology (Shanghai) by Business, 2014-2018
Revenue Structure of Obio Technology (Shanghai) by Business, 2014-2018
Gross Margin of Obio Technology (Shanghai), 2014-2018
R&D Investment of Obio Technology (Shanghai) and % of Total Revenue, 2014-2018
Revenue from Top 5 Clients of Obio Technology (Shanghai) and % in Total Revenue, 2014-2017
Major Clients of Huawe Medicine
Progress of Innovation Projects of Huawe Medicine under R&D
Development Course of Shanghai ChemPartner
Equity Structure of Shanghai ChemPartner’s Subsidiaries
Main Content of Shanghai ChemPartner’s CRO Business
Main Content of Shanghai ChemPartner’s CMO Business
Revenue of Shanghai ChemPartner (by Business), 2015-2018
Revenue Structure of Shanghai ChemPartner (by Business), 2015-2018
Shanghai ChemPartner’s Revenue from Major Customers and % of Total Revenue, 2015-2017
LabCorp’s Revenue and Net Income, 2013-2018
LabCorp’s Revenue (by Division), 2013-2018
LabCorp’s Revenue Structure (by Division), 2013-2018
LabCorp’s CRO Revenue and % of Total Revenue, 2013-2018
Revenue and Net Income of IQVIA, 2014-2018
Operating Revenue of IQVIA by Region and by Business, 2016-2018
Operating Revenue Structure of IQVIA by Region and by Business, 2016-2018
Business Scope of Parexel
Revenue and Net Income of Parexel, FY2014-FY2017
Operating Revenue of Parexel (by Division), FY2014-FY2017
Operating Revenue Structure of Parexel (by Division), FY2014-FY2017
Branches of Parexel in China, as of 2017H1
Revenue and Net Income of Charles River, 2014-2018
Revenue of Charles River (by Division), 2014-2018
Revenue Structure of Charles River (by Division), 2014-2018
Revenue and Net Income of Syneos, 2013-2018
Revenue of Syneos by Business, 2015-2018
Revenue Structure of Syneos by Business, 2015-2018
CRO Revenue and Growth of Syneos, 2015-2018
Revenue and Net Income of PRA, 2014-2018
M&A Course of ICON, 2000-2019
Revenue and Net Income of ICON, 2014-2018
Revenue of ICON by Region, 2016-2018

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号